Adenomyosis.
Conditions
Interventions
Intervention 1: Intervention group 1: Bromocriptine (Iran Hormone Company) in the amount of 2.5 mg, 2 tablets, daily, vaginally for 6 months. Intervention 2: Intervention group 2: Dienogest (Iran Horm
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
35 Years to 50 Years
Inclusion criteria
Inclusion criteria: History of 6 months of painful and regular menstruation
Exclusion criteria
Exclusion criteria: having a history of specific diseases (including epilepsy, gastrointestinal, cardiovascular, renal disorders) according to the person's own statement. allergies to dienogest and bromocriptine Presence of significant gynecological disease or abdominal and pelvic surgery in the last 6 months - Not using gonadotropin agonist or antagonist, hormonal contraceptive in the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: The intensity of pain at the beginning of the study (before the start of the intervention) and 3, 6 and 9 months after the start of taking the drugs vaginal bromocriptine and dinogest. Method of measurement: "Visual pain measurement tool" questionnaires are used to evaluate pain.;Blood loss. Timepoint: The amount of bleeding is checked at the beginning of the study (before the start of the intervention) and 3, 6, and 9 months after starting the use of vaginal bromocriptine and dinogest. Method of measurement: A "visual chart of blood loss" is used to evaluate changes in menstrual symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| State of uterine view. Timepoint: The condition of the uterus is checked at the beginning of the study (before the start of the intervention) and 6, and 9 months after starting the use of vaginal bromocriptine and dinogest. Method of measurement: Vaginal ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvaneh Bahorzehi
Iran University of Medical Sciences
Outcome results
None listed